Personalized Treatments for ALS
Trial Summary
What is the purpose of this trial?
GenieUs developed an analysis platform that will be tested to separate study participants with ALS into four categories based on blood work. These general categories are neuroinflammation, oxidative stress, impaired autophagy \& axonal transport, and mitochondrial dysfunction. Once a disease category is established, participants in this study will receive one of four individualized supplements for 6 months and we will determine whether these are slowing ALS progression: Astaxanthin will be given for the category of neuroinflammation, Protandim for oxidative stress, Melatonin for impaired autophagy and MitoQ for mitochondrial dysfunction. During the first 3 months, participants will have routine monitoring and in months 3 through 9 they will receive the assigned supplement.
Eligibility Criteria
This trial is for individuals with Motor Neuron Disease, specifically Amyotrophic Lateral Sclerosis (ALS). Participants will be categorized based on their blood work into groups reflecting different aspects of ALS pathology and receive personalized supplements accordingly.Inclusion Criteria
Exclusion Criteria
Treatment Details
Interventions
- Astaxanthin (Antioxidant)
- Melatonin (Hormone Therapy)
- MitoQ (Antioxidant)
- Protandim (Antioxidant)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Duke University
Lead Sponsor
Temple University
Collaborator